Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome
C Melander, M Salle, P Trolliet, S Candon… - Clinical Journal of the …, 2009 - journals.lww.com
Background and objectives: Standard treatment for lupus nephritis, including corticosteroids
and cyclophosphamide, is efficient but is still associated with refractory or relapsing disease,
or severe deleterious effects. Rituximab, a monoclonal chimeric anti-B cell antibody, is
increasingly used in patients with lupus nephritis, but reported series were small and had a
short follow-up.
and cyclophosphamide, is efficient but is still associated with refractory or relapsing disease,
or severe deleterious effects. Rituximab, a monoclonal chimeric anti-B cell antibody, is
increasingly used in patients with lupus nephritis, but reported series were small and had a
short follow-up.
以上显示的是最相近的搜索结果。 查看全部搜索结果